1. In-home glucose-lowering medications were not associated with increased mortality or complications among those with COVID-19.
Evidence Rating Level: 2 (Good)
Diabetes is one of the most common comorbidities found among patients with coronavirus disease 2019 (COVID-19), with type 2 diabetes mellitus (T2DM) negatively impacting prognosis in these people. The potential implications of glucose-lowering medications in patients with COVID-19 are currently unclear, however, with metformin showing neutral effects and insulin showing negative effects on in-hospital mortality. This observational, multisite, nationwide cohort study in Spain sought to evaluate the effects of these medications in individuals with T2DM and COVID-19. Data from 2,666 patients (M [SD] age = 74.9 [8.4] years) were initially extracted from the SEMI-COVID-19 Registry who were taking glucose-lowering drugs (1,297 monotherapy, 465 in combination with metformin). Patients using various medications were propensity score-matched. Following matching, patients taking metformin (249), dipeptidyl (105), insulin (129), metformin/dipeptidyl peptidase-4 inhibitors (127), metformin/sedum-glucose cotransporter 2 inhibitor (34), and metformin/insulin (67) were chosen. None of these in-home glucose-lowering medications were associated with in-hospital mortality, duration of stay, or the need for ICU admission. Overall, this study suggests a need for further research to explore the link between T2DM and COVID-19.
©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.